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A grading system (grades 1–3) for follicular lymphoma (FL) is used in the WHO classification for lymphoid malignancies based on the
absolute number of centroblasts in the neoplastic follicles. Grade 3 FL is further subdivided into 3a and 3b depending on the presence
or absence of centrocytes. A total of 231 patients with FL, referred from 1970 to 2001, were identified from our prospectively
maintained database. Original diagnostic materials were available for review on 215 patients and these were reclassified according to
the WHO grading system. Follicular lymphoma grades 1, 2 and 3 accounted for 92, 68 and 55 patients, respectively. No significant
overall survival (OS) differences were observed among FL grades 1–3 (log rank P¼0.25) or between grades 3a and 3b (log rank
P¼0.20). No significant failure-free survival (FFS) differences were observed among FL grades 1–3 (log rank P¼0.72) or between
grades 3a and 3b (log rank P¼0.11). First-line anthracyclines did not influence OS or FFS (log rank P¼0.86, P¼0.58, respectively) in
patients with FL grade 3. There are long-term survivors among patients with FL grade 3 with a continuing risk of relapse.
Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of
anthracyclines should be further evaluated in large randomised studies.
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Non-Hodgkin’s lymphoma (NHL) is increasing in incidence with
more than 287000 cases diagnosed worldwide each year (Ferlay
et al, 2001). Follicular lymphoma (FL) is the second most frequent
type of NHL comprising 22% of all NHL (Armitage and
Weisenburger, 1998). Follicular large cell lymphoma (FLCL) is
an uncommon subtype of FL accounting for 10–40% of FL (Newell
et al, 1987; Martin et al, 1995; Miller et al, 1997; Rodriguez et al,
1999) and only 2–4% of all NHLs (Rosenberg et al, 1982; Newell
et al, 1987). In the US, the incidence rate for FLCL was 0.5 per
100000 in 1998 (Ries et al, 2001).
Over the last two decades, several classifications have been
proposed for NHL. In the Working Formulation (Rosenberg et al,
1982), FLCL is diagnosed when the majority of neoplastic cells
within the follicles are large cleaved or noncleaved cells, although
large noncleaved cells usually predominate. However, the exact
proportion of large cells required to make a diagnosis of FLCL was
not specified. In the Revised European-American Lymphoma
(REAL) classification, a grading system (grades I–III) was
introduced in FL (Harris et al, 1994), but no specific recommenda-
tions for grading criteria were given.
The recently introduced World Health Organisation (WHO)
classification (Nathwani et al, 2001) recommends a similar three-
grade system (grades 1–3) based on counting the absolute number
of centroblasts in 10 neoplastic follicles, expressed per high-power
microscopic field (h.p.f.) of 0.159mm
2. Grade 1 cases have 0–5
centroblasts per h.p.f., grade 2 cases have 6–15 centroblasts per
h.p.f. and grade 3 cases have 415 centroblasts per h.p.f. This
method of histological grading has been shown to predict both
overall survival (OS) and failure-free survival (FFS) (Martin et al,
1995). Furthermore, grade 3 FL can be subdivided for investiga-
tional purposes according to the number of centroblasts. In grade
3a, there are 415 centroblasts per h.p.f., but centrocytes are still
present, while grade 3b has solid sheets of centroblasts with no
centrocytes.
Due to the imprecise method of diagnosing FLCL, relative
infrequency of the disease, small and retrospective nature and
short follow-up of many published studies, there is still
controversy among investigators with regard to its behaviour.
Most importantly, there is no agreement of whether FLCL is
curable, especially when treated with aggressive doxorubicin-
containing regimens. The grading method by Mann and Berard
(1983) used in the WHO classification allows more uniform
reporting of the FL subtypes; the cohort of patients being studied
can therefore be better defined.
Here we report on the long-term follow-up of 215 patients with
FL classified according to the Mann & Berard/WHO grading
system focusing on patients with FL grade 3. The objectives in this
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lreport are: (1) to compare survival of patients with FL grade 3 with
grades 1 and 2, (2) to compare survival of patients with FL grades
3a and 3b, (3) to determine the curability of FL grade 3 with
standard therapy and (4) to compare survival of patients with FL
grade 3 treated with anthracycline or anthracenedione (mitoxan-
trone)-based chemotherapy vs other regimens.
PATIENTS AND METHOD
Between 1970 and 2001, 231 patients with FL were evaluated at the
Royal Marsden Hospital. Medical details, laboratory analyses,
treatment details including previous treatment before presenting
to our institution and treatment outcome were recorded in a
prospectively maintained database. Original diagnostic pathologi-
cal materials obtained at presentation were independently
reviewed by two haematopathologists (AW and PJ) in September
2001 and classified according to the WHO grading system.
Discrepancies were resolved following discussion over a double-
headed microscope and review of centroblast counts. In all, 16
patients were excluded because of missing diagnostic material. A
total of 215 patients formed the cohort in our study of whom 92
had grade 1, 68 had grade 2 and 55 had grade 3 FL (44 had grade 3a
and 11 had grade 3b).
Treatment details
Table 1 shows the details of initial management of the 55 patients
with grade 3 FL. In all, 10 patients had received prior treatment
before presenting to our institution. Seven patients were managed
with deferred therapy initially, five of these patients eventually
required treatment after a median of 21 months (range: 5–122
months). Two patients are still on surveillance only. During follow-
up, patients received a median of two lines of treatment (range:
0–9) in total. For the purpose of analysis, both doxorubicin and
mitoxantrone were considered as anthracyclines. In all, 14 patients
received anthracycline-based combination as subsequent treat-
ment including six who received their first anthracycline-based
chemotherapy after transformation into diffuse large cell histology.
In total, 25 patients did not receive any anthracycline, including
seven who received radiotherapy (RT) alone.
Statistical analysis
Baseline characteristics among three grades of FL were compared
using the w
2 test for categorical variables (gender, stage, systemic
symptoms and performance status). Continuous variables (serum
lactate dehydrogenase (LDH) and age) were tested for normality
using the Kolmogorov–Smirnov test. Analysis of variance
(ANOVA) was used for continuous variables with normal
distribution (age) and Kruskal–Wallis test was used for contin-
uous variables with non-normal distribution (LDH).
Overall survival was calculated from the date of diagnosis until
death from any cause or last follow-up. Failure-free survival was
calculated from the date of diagnosis until disease progression,
relapse, death from any cause or last follow-up evaluation. Cause-
specific survival (CSS) was calculated from the date of diagnosis
until death due to disease or treatment toxicity. Overall survival,
FFS and CSS were estimated using the Kaplan–Meier method
(Kaplan and Meier, 1958). Comparisons of survival curves were
performed using the log-rank test (Peto and Peto, 1972).
Univariate analysis was performed in patients with FL grade 3
using forward stepwise Cox proportional hazards regression
modelling (Cox and Oakes, 1984). Age, performance status, LDH,
haemoglobin, platelet count, white blood cell and lymphocyte
count, albumin, alkaline phosphatase, erythrocyte sedimentation
rate (ESR) and b2 microglobulin were used as continuous
variables. Gender, stage of disease (IþII vs IIIþIV), systemic
symptoms (presence vs absence), bulky disease over 5cm
(presence vs absence), marrow involvement (presence vs absence)
and first-line use of anthracycline-based chemotherapy (yes vs no)
were used as categorical variables. Data were analysed using the
SPSS package version 10.1.4 (SPSS Inc. Chicago, IL, USA) in
January 2002.
RESULTS
Clinical features
Table 2 shows the clinical features of patients with all three grades of
FL. No statistical differences in baseline clinical features were observed
among them. Nine patients (16%) with FL grade 3 had subsequent
transformation to diffuse large cell histology during follow-up.
Outcome
The median follow-up for grades 1, 2 and 3 was 54.7, 57.2 and 79.6
months, respectively. No survival differences were observed among
grades 1–3 (log rank P¼0.25, Figure 1). The median survival for
grades 1, 2 and 3 was 14, 9.2 and 22.2 years, respectively. Overall
survival rates at 10 years were 59.5% (95% confidence interval
(CI)¼45.4–71.1%), 48.7% (95% CI¼32.2–63.3%) and 69.2%
(95% CI¼50.2–82.2%) for grades 1, 2 and 3, respectively. No CSS
differences in grades 1–3 were observed (log rank P¼0.65,
Figure 2). Cause-specific survival rates at 10 years were 71.1%
(95% CI¼57–81.4%), 66.3% (95% CI¼46.8–80%) and 74.1%
(95% CI¼53.9–86.5%) for grades 1, 2 and 3, respectively. No FFS
differences were observed among grades 1, 2 and 3 (log rank
P¼0.72, Figure 3). Failure-free survival rates at 10 years were
25.5% (95% CI¼14.9–37.6%), 31.2% (95% CI¼18.0–45.3%) and
28.8% (95% CI¼14.4–44.9%) for grades 1–3, respectively.
Restricting the analysis to FL grades 3a and 3b, the median
follow-up was 82.2 and 56.9, months, respectively. No overall
survival difference was observed between 3a and 3b (log rank
P¼0.20, Figure 4A). The median survival was 11.5 and 22.2 years
for grades 3a and 3b, respectively. Overall survival rates at 10 years
Table 1 Initial management of patients with follicular lymphoma grade 3
Treatment Number (total n¼55)
Anthracycline-based chemotherapy n¼15
CHOP (+RT) 8 (+1)
FMD 1
FAD 3
MACOP-B 1
PMitCEBO 1
Nonanthracycline-based chemotherapy n¼21
Chlorambucil/prednisolone 3
Chlorambucil 6
COP/CVP 7
CVP+rituximab 3
Fludarabine 1
LOP 1
Radiotherapy n¼12
Involved field 9
Extended field 3
Surveillance n¼7
CHOP¼cyclophosphamide, doxorubicin, vincristine and prednisolone; RT¼
radiotherapy; FMD¼fludarabine, mitoxantrone, dexamethasone; FAD¼fludarabine,
udarabine, doxorubicin, dexamethasone; MACOP-B¼methotrexate, doxorubicin,
cyclophosphamide, vincristine, prednisolone and bleomycin; PMitCE-
BO¼prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin and
vincristine; COP/CVP¼cyclophosphamide, vincristine and prednisolone. Drugs are
given in different doses and schedules in COP and CVP; LOP¼lomustine, vincristine
and prednisolone.
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lwere 61.7% (95% CI¼39.8–77.7%) and 100% (not possible to
calculate the 95% CI as no events have occurred) for grades 3a and
3b, respectively. No CSS difference was observed between 3a and
3b (log rank P¼0.11, Figure 4B). Cause-specific survival rates at
10 years were 67.3% (95% CI¼43.4–82.9%) and 100% for grades
3a and 3b, respectively. No FFS difference was observed between
grades 3a and 3b (log rank P¼0.11, Figure 4C). Failure-free
survival rates at 10 years were 23.5% (95% CI¼10–40.3%) and
57.9% (95% CI¼15.3–85.2%) for grades 3a and 3b, respectively.
A total of 40 patients with FL grade 3 are alive. Among them, 18
patients are in continuous remission after first therapy. Of the 15
patients who died, nine died of lymphoma. Six died from unrelated
causes including two from second primary malignancy, two from
infection, one from chronic renal failure and one from pulmonary
embolism. No patients died of cardiovascular disease. Both
fatalities in patients with FL grade 3b resulted from colorectal
cancer 22 and 10 years after the initial diagnosis of follicular
lymphoma.
No survival difference was seen between patients with FL grade 3
who received anthracycline-based chemotherapy as first-line
therapy (the A1 group) and those who did not (the non-A1 group)
(log rank P¼0.86, Figure 5A). However, no deaths were observed
after 4 years in the A1 group. Even when patients with limited
stage disease who received RT only as first-line therapy were
excluded, no survival difference was seen between the A1 group
and the non-A1 group (log rank P¼0.67, Figure 5B).
No FFS difference was seen between the A1 group and the non-
A1 group (log rank P¼0.58, Figure 6A). However, no relapses
were observed after 5 years in the A1 group. Even when patients
with limited stage disease who received RT only as first-line
therapy were excluded, no FFS difference was seen between the A1
and the non-A1 groups (log rank P¼0.39, Figure 6B).
In order to investigate whether anthracycline-based chemother-
apy may be more beneficial in either grade 3a or 3b, a further
Table 2 Patient characteristics
Number of patients (%)
Clinical features Grade 1 Grade 2 Grade 3 P-value
Total number of
patients
92 68 55
Median age (years)
(range)
49 (28–87) 54.5 (34–78) 53 (18–81) 0.57
Gender
Male 38 31 29 0.40
Female 54 37 26
Stage at presentation
I 9 (9.8) 12 (17.6) 13 (23.6)
II 7 (7.6) 11 (16.2) 6 (10.9) 0.09
III 25 (27.2) 20 (29.4) 15 (27.3)
IV 51 (55.4) 25 (36.8) 21 (38.2)
Systemic symptoms
Absent 68 (73.9) 52 (76.5) 42 (76.4) 0.92
Present 24 (26.1) 16 (23.5) 13 (23.6)
Performance status
0–1 53 (57.6) 36 (52.9) 39 (70.9)
2–4 1 (1.1) 5 (7.4) 4 (7.3) 0.62
Unknown 38 (41.3) 27 (39.7) 12 (21.8) (0.129)
a
LDH
Normal 39 (42.4) 31 (45.6) 20 (36.3)
Elevated 19 (20.7) 12 (17.6) 10 (18.2) 0.72
b
Unknown 34 (37.0) 25 (36.8) 25 (45.5)
LDH¼lactate dehydrogenase.
aIf patients with unknown performance status are excluded.
bUsing Kruskal–Wallis test.
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Figure 1 Overall survival of follicular lymphoma by grade (years).
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Figure 2 Cause-specific survival of follicular lymphoma by grade (years).
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lanalysis was performed. Patients with FL grade 3a or 3b were
divided according to whether they received anthracycline or
nonanthracycline-based regimen as their first chemotherapy
regimen. This therefore included patients who initially received
RT but experienced disease relapse or progression, and patients
who were initially on surveillance but required chemotherapy. In
patients with FL grade 3a, a similar proportion of patients
experienced disease relapse or progression whether they received
anthracycline or nonanthracycline-based chemotherapy (P¼0.76).
However, in patients with FL grade 3b and who had received
anthracycline-based chemotherapy, none experienced disease
relapse or progression (Table 3).
Factors predicting survival
Univariate analysis was performed to identify predictive factors for
survival in patients with FL grade 3 (Table 4). Increasing age, poor
performance status, elevated LDH, elevated b2 microglobulin and
stage III–IV disease were found to be significant or borderline
significant poor prognostic factors. Normal or elevated level of
albumin was a favourable prognostic factor. First-line treatment
with anthracycline-based chemotherapy was not found to be
significant. However, multivariate analysis was not performed
because first only 15 events have occurred in patients with FL
grade 3, second 10 patients had prior treatment before presenting
to our institution and third, some of the baseline laboratory
analyses were not available.
DISCUSSION
The natural history of FL is often considered as having an indolent
growth pattern, but remains essentially incurable when
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Figure 3 Failure-free survival of follicular lymphoma by grade.
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Figure 4 Survival for grade 3a and 3b follicular lymphoma: (A) overall
survival; (B) cause-specific survival; (C) failure-free survival.
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Figure 5 Survival for patients with grade 3 follicular lymphoma receiving
anthracyclines. (A) Overall survival for all patients with grade 3 follicular
lymphoma. A1 group includes patients who received anthracyclines as their
first-line treatment. Non-A1 group includes patients who did not receive
anthracyclines as their first-line treatment. (B) Overall survival for patients
with grade 3 follicular lymphoma excluding those with limited disease and
received radiotherapy only as initial treatment.
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ldisseminated. Because of the inconsistent histological criteria for
making the diagnosis of FLCL, many of the reported series may not
be directly comparable. Nevertheless, it emerges from the
published literature that, unlike other subtypes of FL, a small
group of patients is free of disease with prolonged follow-up. The
Mann & Berard grading system adopted by the WHO provides a
more uniform system of diagnosing different subtypes of FL,
therefore allowing a more consistent approach in defining the
patient cohort.
In our first objective to compare survival of patients with FL
grade 3 with grades 1 and 2, we found no significant differences
among the histological grades. Two series in the literature reported
contradictory results (Martin et al, 1995; Miller et al, 1997). In the
Nebraska study, 64 patients with FLCL diagnosed using the Mann
& Berard method had worse survival compared to the combined
group of 42 patients with follicular small cell and follicular mixed
cell lymphoma patients (P¼0.0035). In contrast, Miller et al (1997)
reported the long-term outcome of 389 patients registered on
SWOG studies. No differences in OS among the three follicular
histological subgroups were found (P¼0.40). Our 10-year survival
of 69.2% in patients with FL grade 3 compared well with other
series (Table 5). Although our inclusion of stage I and II disease
patients may explain the better survival, our long-term outcome
still compares favourably with series which included stage I and II
only (Tezcan et al, 1999).
Although there is no difference in CSS among grades 1, 2 and 3,
no disease-related deaths occurred beyond 10 years for grade 3.
This suggests that a proportion of patients may be potentially
curable or successfully salvaged, but prolonged survival means that
patients may die from unrelated causes. A long-term follow-up of
62 patients from the MD Anderson series treated between 1973 and
1981 showed that lymphoma-related mortality continued to occur
beyond 15 years (Rodriguez et al, 2000) suggesting that longer
follow-up for our cohort of patients is necessary before this plateau
in CSS can be confirmed. No difference in FFS was observed
among grades 1–3. Patients with FL grade 3 had a continuing risk
of relapses with 10 patients relapsing after 5 years. Although no
relapses have been observed beyond 9 years, only five patients are
failure free at this time point. Again longer follow-up and larger
patient number are necessary to determine the curability of
grade 3.
Our study provides an opportunity to examine the difference in
behaviour between grades 3a and 3b. There does not appear to be
any survival differences between grades 3a and 3b. However, the
small number of patients with grade 3b in this study means only
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Figure 6 Failure-free survival for patients with grade 3 follicular
lymphoma receiving anthracyclines: (A) for all patients with grade 3
follicular lymphoma and (B) for patients with grade 3 follicular lymphoma
excluding those with limited disease and received radiotherapy only as
initial treatment.
Table 3 Patients with follicular lymphoma grade 3 receiving anthracy-
cline as first chemotherapy regimen including those who relapsed after
initial radiotherapy and those who progressed during initial surveillance
Number of patients
Grade 3a Grade 3b
First-line anthracycline-based chemotherapy 13 4
Disease relapse/progression 9 0
First-line nonanthracycline-based chemotherapy 23 5
Disease relapse/progression 17 2
Table 4 Univariate analysis of patients with follicular lymphoma grade 3
95% Confidence
interval
Factors
Hazard
ratio
Lower
limit
Upper
limit P-value
Age 1.036 0.995 1.08 0.085
Performance status 2.239 1.018 4.924 0.045
LDH 1.003 1.000 1.006 0.086
b2-microglobulin 8.205 1.528 44.063 0.014
Stage III–IV 3.944 0.879 17.701 0.073
Serum albumin 0.661 0.463 0.943 0.022
First-line treatment with
anthracyclines
0.89 0.246 3.218 0.86
Table 5 Survival of patients with follicular large cell lymphoma in recently
reported series
Studies
5-year overall
survival (%)
10-year overall
survival (%)
Our study (2002)
a 78 (95% CI: 63–88%) 69 (95% CI: 50–82%)
Nebraska study
(Anderson et al, 1993)
45 NS
Stanford study (Bartlett
et al, 1994)
75 54
GELA (Wendum et al,
1997)
58 NS
SWOG study (Miller
et al, 1997)
NS 37
Nebraska study (Tezcan
et al, 1999) stage I–II
NS 44
MD Anderson
(Rodriguez et al, 1999)
72 NS
MD Anderson
(Rodriguez et al, 2000)
NS 31
CI¼confidence interval. NS¼not stated in publications.
aPatients with follicular
lymphoma grade 3.
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l10-year survival differences in excess of 30% between grades 3a
and 3b could be detected with at least 80% power. Nevertheless, it
is interesting that no patients with FL grade 3b died of lymphoma
and both deaths in patients with FL grade 3b resulted from second
primary colorectal cancers. No difference in FFS was, however,
evident between grades 3a and 3b with late relapses after 5 years
occurring in both groups. No definitive curability could be seen yet
with either grade 3a or grade 3b.
The Working Formulation classified FLCL into an intermediate
grade NHL together with diffuse large B cell non-Hodgkin’s
lymphoma (DLBCL). As a result, researchers often treated these
patients with intensive anthracycline-containing chemotherapy
similar to those used in DLBCL. The majority of the patients in the
recently reported series have been treated with anthracyclines
(Anderson et al, 1993; Bartlett et al, 1994; Miller et al, 1997;
Wendum et al, 1997; Rodriguez et al, 1999, 2000; Tezcan et al,
1999). Even with series that included patients treated with
nonanthracycline-containing therapy, only patients treated in the
1970s or patients with a history of cardiac disease were offered
routine nonanthracycline-containing therapy (Bartlett et al, 1994).
No conclusive randomised evidence is available in this uncommon
disease entity to test the role of anthracycline-based therapy as
first-line treatment. In addition, patient selection, referral pattern
and variation in diagnostic criteria between institutions and over
the years at the same institution have hampered a clear
understanding of the behaviour of this disease.
We investigated whether patients with FL grade 3 treated with
anthracycline-based chemotherapy as first-line therapy (A1 group)
had a better outcome than those treated with other regimens (non-
A1 group). No survival differences were observed between the A1
group and the non-A1 group even when patients with limited stage
who received RT alone were excluded. However, no events in OS or
FFS occurred after 4 years in the A1 group suggesting that some
patients were possibly cured by anthracyclines. This is relatively
promising for FL as FL grade 1 and grade 2 had a constant rate of
recurrence or progression. Nevertheless, long-term survivors also
occurred in the non-A1 group suggesting that a subgroup of
patients could be spared from the potential morbidity of
anthracyclines, especially the elderly. This is particularly relevant
with the introduction of anti-CD-20-targeted therapy such as
rituximab,
131I-labelled tositumomab and
90Y-labelled ibratumo-
mab. Rituximab has shown activity in relapsed FLCL as a single
agent (McLaughlin et al, 1998). It has also been shown to have
superior survival in elderly patients with DLBCL when used in
combination with regimen including cyclophosphamide, doxor-
ubicin, vincristine and prednisolone (CHOP) compared with
CHOP alone (Coiffier et al, 2002). The incorporation of these
targeted therapies into combination chemotherapy may obviate
the need for anthracyclines in the front-line therapy of FL grade 3.
In our series, patients with FL grade 3b did not experience disease
relapse or progression after receiving anthracycline-based che-
motherapy. Whereas this was a small subgroup analysis and
should be interpreted with caution, the trend in favour of better
outcome for grade 3b patients may suggest that they represent a
biologically distinct group compared with patients with grade 3a,
especially when treated with anthracycline-based chemotherapy.
The international prognostic index (IPI) (The International
Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993)
originally developed for aggressive lymphoma has been shown to
correlate with the outcome of patients with FLCL (Bartlett et al,
1994; Rodriguez et al, 1999, 2000) The international prognostic
index could therefore be used to aid clinical decision making. Since
not all baseline performance status and laboratory results were
available for the present analysis and because some patients were
treated nearly 30 years ago and some received initial treatment at
another institution, it was decided not to construct a retrospective
prognostic model using the available data.
In conclusion, there are long-term survivors among FL grade 3
patients with a continuing risk of relapse. Anthracyclines did not
appear to influence survival or disease relapses when given as
front-line therapy in our series. Given the caveat that the number
of patients with grade 3 (especially grade 3b) in our series was very
small, these data are hypothesis-generating. The role of anthracy-
clines in FL grade 3 patients should therefore be further evaluated
in large randomised studies especially with the advent of anti-CD-
20-targeted therapy.
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